Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases

Louis S. Matza, Ze Cong, Karen Chung, Alison T Stopeck, Katia Tonkin, Janet Brown, Ada Braun, Kate Van Brunt, Kelly McDaniel

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Introduction: Although cost-utility models are often used to estimate the value of treatments for metastatic cancer, limited information is available on the utility of common treatment modalities. Bisphosphonate treatment for bone metastases is frequently administered via intravenous infusion, while a newer treatment is administered as a subcutaneous injection. This study estimated the impact of these treatment modalities on health state preference. Methods: Participants from the UK general population completed time trade-off interviews to assess the utility of health state vignettes. Respondents first rated a health state representing cancer with bone metastases. Subsequent health states added descriptions of treatment modalities (ie, injection or infusion) to this basic health state. The two treatment modalities were presented with and without chemotherapy, and infusion characteristics were varied by duration (30minutes or 2hours) and renal monitoring. Results: A total of 121 participants completed the interviews (52.1% female, 76.9% white). Cancer with bone metastases had a mean utility of 0.40 on a standard utility scale (1=full health; 0=dead). The injection, 30-minute infusion, and 2-hour infusion had mean disutilities of -0.004, -0.02, and -0.04, respectively. The mean disutility of the 30-minute infusion was greater with renal monitoring than without. Chemotherapy was associated with substantial disutility (-0.17). When added to health states with chemotherapy, the mean disutilities of injection, 30-minute infusion, and 2-hour infusion were -0.02, -0.03, and -0.04, respectively. The disutility associated with injection was significantly lower than the disutility of the 30-minute and 2-hour infusions (P<0.05), regardless of chemotherapy status. Conclusion: Respondents perceived an inconvenience with each type of treatment modality, but injections were preferred over infusions. The resulting utilities may be used in cost-utility models examining the value of treatments for the prevention of skeletal-related events in patients with bone metastases.

Original languageEnglish (US)
Pages (from-to)855-865
Number of pages11
JournalPatient Preference and Adherence
Volume7
DOIs
StatePublished - Jan 2013

Fingerprint

Subcutaneous Infusions
Subcutaneous Injections
Intravenous Infusions
Neoplasm Metastasis
Bone and Bones
health
Health
cancer
Injections
Drug Therapy
Bone Neoplasms
Therapeutics
monitoring
Interviews
costs
interview
Kidney
Costs and Cost Analysis
available information
Values

Keywords

  • Infusion
  • Injection
  • Skeletal-related event

ASJC Scopus subject areas

  • Social Sciences (miscellaneous)
  • Medicine (miscellaneous)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. / Matza, Louis S.; Cong, Ze; Chung, Karen; Stopeck, Alison T; Tonkin, Katia; Brown, Janet; Braun, Ada; Van Brunt, Kate; McDaniel, Kelly.

In: Patient Preference and Adherence, Vol. 7, 01.2013, p. 855-865.

Research output: Contribution to journalArticle

Matza, Louis S. ; Cong, Ze ; Chung, Karen ; Stopeck, Alison T ; Tonkin, Katia ; Brown, Janet ; Braun, Ada ; Van Brunt, Kate ; McDaniel, Kelly. / Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. In: Patient Preference and Adherence. 2013 ; Vol. 7. pp. 855-865.
@article{faf4876752564ec1984b3eb6894bd95e,
title = "Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases",
abstract = "Introduction: Although cost-utility models are often used to estimate the value of treatments for metastatic cancer, limited information is available on the utility of common treatment modalities. Bisphosphonate treatment for bone metastases is frequently administered via intravenous infusion, while a newer treatment is administered as a subcutaneous injection. This study estimated the impact of these treatment modalities on health state preference. Methods: Participants from the UK general population completed time trade-off interviews to assess the utility of health state vignettes. Respondents first rated a health state representing cancer with bone metastases. Subsequent health states added descriptions of treatment modalities (ie, injection or infusion) to this basic health state. The two treatment modalities were presented with and without chemotherapy, and infusion characteristics were varied by duration (30minutes or 2hours) and renal monitoring. Results: A total of 121 participants completed the interviews (52.1{\%} female, 76.9{\%} white). Cancer with bone metastases had a mean utility of 0.40 on a standard utility scale (1=full health; 0=dead). The injection, 30-minute infusion, and 2-hour infusion had mean disutilities of -0.004, -0.02, and -0.04, respectively. The mean disutility of the 30-minute infusion was greater with renal monitoring than without. Chemotherapy was associated with substantial disutility (-0.17). When added to health states with chemotherapy, the mean disutilities of injection, 30-minute infusion, and 2-hour infusion were -0.02, -0.03, and -0.04, respectively. The disutility associated with injection was significantly lower than the disutility of the 30-minute and 2-hour infusions (P<0.05), regardless of chemotherapy status. Conclusion: Respondents perceived an inconvenience with each type of treatment modality, but injections were preferred over infusions. The resulting utilities may be used in cost-utility models examining the value of treatments for the prevention of skeletal-related events in patients with bone metastases.",
keywords = "Infusion, Injection, Skeletal-related event",
author = "Matza, {Louis S.} and Ze Cong and Karen Chung and Stopeck, {Alison T} and Katia Tonkin and Janet Brown and Ada Braun and {Van Brunt}, Kate and Kelly McDaniel",
year = "2013",
month = "1",
doi = "10.2147/PPA.S44947",
language = "English (US)",
volume = "7",
pages = "855--865",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases

AU - Matza, Louis S.

AU - Cong, Ze

AU - Chung, Karen

AU - Stopeck, Alison T

AU - Tonkin, Katia

AU - Brown, Janet

AU - Braun, Ada

AU - Van Brunt, Kate

AU - McDaniel, Kelly

PY - 2013/1

Y1 - 2013/1

N2 - Introduction: Although cost-utility models are often used to estimate the value of treatments for metastatic cancer, limited information is available on the utility of common treatment modalities. Bisphosphonate treatment for bone metastases is frequently administered via intravenous infusion, while a newer treatment is administered as a subcutaneous injection. This study estimated the impact of these treatment modalities on health state preference. Methods: Participants from the UK general population completed time trade-off interviews to assess the utility of health state vignettes. Respondents first rated a health state representing cancer with bone metastases. Subsequent health states added descriptions of treatment modalities (ie, injection or infusion) to this basic health state. The two treatment modalities were presented with and without chemotherapy, and infusion characteristics were varied by duration (30minutes or 2hours) and renal monitoring. Results: A total of 121 participants completed the interviews (52.1% female, 76.9% white). Cancer with bone metastases had a mean utility of 0.40 on a standard utility scale (1=full health; 0=dead). The injection, 30-minute infusion, and 2-hour infusion had mean disutilities of -0.004, -0.02, and -0.04, respectively. The mean disutility of the 30-minute infusion was greater with renal monitoring than without. Chemotherapy was associated with substantial disutility (-0.17). When added to health states with chemotherapy, the mean disutilities of injection, 30-minute infusion, and 2-hour infusion were -0.02, -0.03, and -0.04, respectively. The disutility associated with injection was significantly lower than the disutility of the 30-minute and 2-hour infusions (P<0.05), regardless of chemotherapy status. Conclusion: Respondents perceived an inconvenience with each type of treatment modality, but injections were preferred over infusions. The resulting utilities may be used in cost-utility models examining the value of treatments for the prevention of skeletal-related events in patients with bone metastases.

AB - Introduction: Although cost-utility models are often used to estimate the value of treatments for metastatic cancer, limited information is available on the utility of common treatment modalities. Bisphosphonate treatment for bone metastases is frequently administered via intravenous infusion, while a newer treatment is administered as a subcutaneous injection. This study estimated the impact of these treatment modalities on health state preference. Methods: Participants from the UK general population completed time trade-off interviews to assess the utility of health state vignettes. Respondents first rated a health state representing cancer with bone metastases. Subsequent health states added descriptions of treatment modalities (ie, injection or infusion) to this basic health state. The two treatment modalities were presented with and without chemotherapy, and infusion characteristics were varied by duration (30minutes or 2hours) and renal monitoring. Results: A total of 121 participants completed the interviews (52.1% female, 76.9% white). Cancer with bone metastases had a mean utility of 0.40 on a standard utility scale (1=full health; 0=dead). The injection, 30-minute infusion, and 2-hour infusion had mean disutilities of -0.004, -0.02, and -0.04, respectively. The mean disutility of the 30-minute infusion was greater with renal monitoring than without. Chemotherapy was associated with substantial disutility (-0.17). When added to health states with chemotherapy, the mean disutilities of injection, 30-minute infusion, and 2-hour infusion were -0.02, -0.03, and -0.04, respectively. The disutility associated with injection was significantly lower than the disutility of the 30-minute and 2-hour infusions (P<0.05), regardless of chemotherapy status. Conclusion: Respondents perceived an inconvenience with each type of treatment modality, but injections were preferred over infusions. The resulting utilities may be used in cost-utility models examining the value of treatments for the prevention of skeletal-related events in patients with bone metastases.

KW - Infusion

KW - Injection

KW - Skeletal-related event

UR - http://www.scopus.com/inward/record.url?scp=84884132445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884132445&partnerID=8YFLogxK

U2 - 10.2147/PPA.S44947

DO - 10.2147/PPA.S44947

M3 - Article

C2 - 24039408

AN - SCOPUS:84884132445

VL - 7

SP - 855

EP - 865

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -